Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule by Witek, Małgorzata A. et al.
Discrete microfluidics for the isolation of circulating tumor cell 
subpopulations targeting fibroblast activation protein alpha and 
epithelial cell adhesion molecule
Małgorzata A. Witek1,2,3, Rachel D. Aufforth4, Hong Wang3, Joyce W. Kamande3, Joshua M. 
Jackson1,2, Swathi R. Pullagurla1,2, Mateusz L. Hupert3,5, Jerry Usary6,7, Weiya Z. 
Wysham7,8, Dawud Hilliard7,9, Stephanie Montgomery9,10, Victoria Bae-Jump7,8, Lisa A. 
Carey7,11, Paola A. Gehrig7,8, Matthew I. Milowsky7, Charles M. Perou7, John T. Soper7,8, 
Young E. Whang7, Jen Jen Yeh4,7,12, George Martin13, and Steven A. Soper14,15,16
1Department of Chemistry, The University of Kansas, Lawrence, KS 66047, USA
2Center of Biomodular Multiscale Systems for Precision Medicine, The University of Kansas, 
Lawrence, KS 66047, USA
3Department of Biomedical Engineering, The University of North Carolina, Chapel Hill, NC 27599, 
USA
4Department of Surgery, The University of North Carolina, Chapel Hill, NC 27599, USA
5BioFluidica, Inc., c/o Carolina Kick-Start, 321 Bondurant Hall, Chapel Hill NC27599, USA
6Department of Genetics, The University of North Carolina, Chapel Hill, NC 27599, USA
7Lineberger Comprehensive Cancer Center, The University of North Carolina, Chapel Hill, NC 
27599, USA
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party 
material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Jen Jen Yeh (jen_jen_yeh@med.unc.edu) or George Martin (george.martin@roche.com) or Steven A. Soper 
(ssoper@ku.edu). 
AUTHOR CONTRIBUTIONS
M.A.W., R.D.A., H.W., and J.W.K. designed and performed the experiments, developed protocols for molecular profiling, mutation 
detection, cell staining, and performed data interpretation. J.M.J.: computational fluid dynamic simulations, data analysis. S.R. P.: 
CTC imaging. M.L.H. and S.A.S.: design and fabrication of the microfluidic devices. J.U.: tumor tissue and blood collection from 
breast cancer mouse models. D.H. and SM.: tissue staining. R.D.A. and W.Z.W.: patient recruitment and consent and information on 
patients’ disease status. V.B.J., L.A.C., P.A.G., M.I.M., C.M.P., J.T.S., Y.E.W., and J.J.Y.: composed and maintained the I.R.B., 
recruited patients, assisted in the analysis of the C.T.C. data. G.M.: contributed to the general concept of research and assisted in the 
analysis of the C.T.C. data. S.A.S. and C.M.P.: designed experiments and data analysis. M.A.W., J.M.J., R.D.A., J.J.Y., J.M.J., and 
S.A.S.: wrote manuscript. All authors read the manuscript.
Supplementary Information accompanies the paper on the npj Precision Oncology website (doi:10.1038/s41698-017-0028-8).
Competing interests: The presented CTC isolation technology is being commercialized by Biofluidica, Inc. S.A.S. and M.L.H. hold 
equity shares in BioFluidica, Inc. M.A.W. declares conflict of interest as spouse of M.L.H. The remaining authors declare that they 
have no competing financial interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
HHS Public Access
Author manuscript
NPJ Precis Oncol. Author manuscript; available in PMC 2018 April 11.
Published in final edited form as:













8Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, UNC-Chapel Hill, 
NC 27599, USA
9Animal Histopathology Core, The University of North Carolina, Chapel Hill, NC 27599, USA
10Department of Pathology and Laboratory Medicine, The University of North Carolina, Chapel 
Hill, NC 27599, USA
11Department of Medicine, Division of Hematology and Oncology, The University of North 
Carolina, Chapel Hill, NC 27599, USA
12Department of Pharmacology, The University of North Carolina, Chapel Hill, NC 27599, USA
13Roche, Pleasanton, CA 94588, USA
14BioEngineering Program, The University of Kansas, Lawrence, KS 66047, USA
15Department of Mechanical Engineering, The University of Kansas, Lawrence, KS 66047, USA
16Ulsan National Institute of Science and Technology, Ulsan, Republic of Korea
Abstract
Circulating tumor cells consist of phenotypically distinct subpopulations that originate from the 
tumor microenvironment. We report a circulating tumor cell dual selection assay that uses discrete 
microfluidics to select circulating tumor cell subpopulations from a single blood sample; 
circulating tumor cells expressing the established marker epithelial cell adhesion molecule and a 
new marker, fibroblast activation protein alpha, were evaluated. Both circulating tumor cell 
subpopulations were detected in metastatic ovarian, colorectal, prostate, breast, and pancreatic 
cancer patients and 90% of the isolated circulating tumor cells did not co-express both antigens. 
Clinical sensitivities of 100% showed substantial improvement compared to epithelial cell 
adhesion molecule selection alone. Owing to high purity (>80%) of the selected circulating tumor 
cells, molecular analysis of both circulating tumor cell subpopulations was carried out in bulk, 
including next generation sequencing, mutation analysis, and gene expression. Results suggested 
fibroblast activation protein alpha and epithelial cell adhesion molecule circulating tumor cells are 
distinct subpopulations and the use of these in concert can provide information needed to navigate 
through cancer disease management challenges.
INTRODUCTION
Methods relying on anti-epithelial cell adhesion molecule (EpCAM) for positive affinity-
selection of circulating tumor cells (CTCs) has been cleared by the Food and Drug 
Administration (FDA) for metastatic breast, prostate, and colorectal cancers; however, 
enumeration of EpCAM(+) CTCs alone has demonstrated modest clinical sensitivity.1 
EpCAM-bearing CTCs may not be the only “players” in cancer progression. For example, 
CTCs undergoing epithelial-to-mesenchymal transitions2 lose epithelial antigens due to 
phenotypic plasticity. Additionally, the tumor microenvironment is composed of 
phenotypically distinct cells that may be involved in disease progression.3 Therefore, for 
CTC selection it becomes necessary to consider orthogonal markers in combination with the 
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epithelial ones to improve clinical sensitivity, patient stratification, disease recurrence 
monitoring, and/or therapeutic guidance.
The use of multiple affinity-selection markers has been attempted with a combination of 
monoclonal antibodies, mAbs (i.e., EpCAM plus TROP-2, HER-2, and CD44).4 In 
metastatic cancer patients, this strategy recovered EpCAM-negative cells that were 
cytokeratin (CK)-positive, contrasting with the classical CTC definition of EpCAM+/CK+/
CD45−4. While recovering CTCs on mixed monolayers of mAbs has been reported, 
subpopulations cannot be independently interrogated unless elaborate single-cell analysis is 
employed. Additionally, because CTC affinity-selection depends upon the mAb surface 
concentration, mixed monolayers can reduce recovery, especially when CTCs express low 
antigen levels. Positive CTC selection markers have included prostate-specific membrane 
antigen (PSMA), chemokine receptors, CD133, VCAM-1, MCAM (CD146), ICAM-1, 
CEA, HER-2, N-cadherin (CDH2)/O-cadherin (CDH11), and MUC1.5–7 Some of these 
antigens target only a particular cancer (i.e., PSMA) or lack cancer-specificity (CD133, 
VCAM-1, ICAM-1) as hematopoietic/endothelial/benign cells also expressed these antigens,
8–11 producing low CTC purity and confounding clinical interpretations of the data. Other 
markers (MUC1) are co-expressed with EpCAM and thus provide modest improvement in 
clinical sensitivity.6
We report a CTC selection strategy that uses serially connected microfluidic chips (i.e., 
discrete microfluidics) to affinity-select two CTC subpopulations expressing EpCAM and 
fibroblast activation protein alpha (FAPα).12 FAPα expression has been observed in >90% 
of human epithelial cancers and has been associated with mesenchymal characteristics and 
cell invasion of the extracellular matrix.13 Our choice for investigating FAPα CTCs was 
further guided by data from the Human Protein Atlas, which indicated mutually 
independent, orthogonal expression of FAPα and EpCAM across many cancer cell lines 
(Supplementary Fig. S1). FAPα has been identified via staining in CTCs that invade a cell 
adhesion matrix (CAM),14 but to date, affinity-selection of FAPα and EpCAM-bearing CTC 
subpopulations for enumeration from clinical samples, molecular profiling, and longitudinal 
surveillance has not been undertaken.
We hypothesized that FAPα can be used as an additional marker for selecting a 
phenotypically distinct CTC subpopulation with respect to a CTC subpopulation that 
expresses EpCAM. In addition, parsing these subpopulations into different fractions could 
provide molecular characteristics of distinct cancer cell phenotypes that could be useful in 
better predicting clinical outcomes.
RESULTS
Microfluidic CTC selection strategy
To demonstrate the utility of the dual selection assay for CTCs in this study, we employed 
sinusoidal microfluidics for CTC affinity isolation (Fig. 1a–c). The microfluidic chips 
process whole, unfractionated, and unfixed blood and use sinusoidal microchannels (Fig. 1b) 
to encourage interactions between flowing CTCs and mAbs decorated on the device’s 
surfaces (Fig. 1c, d) for affinity isolation. In previous reports, we have characterized the 
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sinusoidal technology for its operating principles and performance,15–20 isolated EpCAM+ 
CTCs in patients with localized and metastatic pancreatic ductal adenocarcinoma (L-PDAC 
and M-PDAC, respectively),17 metastatic epithelial ovarian cancer (M-EOC),18 and patient-
derived xenograft pancreatic ductal adenocarcinoma (PDAC) mouse models.20, 21 We also 
applied this technology for residual disease evaluation in multiple myeloma18 and acute 
myeloid leukemia19 patients, as well as T-cells and neutrophil isolation for stroke 
diagnostics.22 The sinusoidal technology offers high CTC recovery from clinical samples 
while achieving exquisite purity that enabled much of the molecular profiling reported 
herein (Fig. 1g).
In this study, we selected both FAPα+ and EpCAM+ cells from a single blood sample by 
arranging two microfluidic devices in series, one chip targeting FAPα+ and the other 
EpCAM+ cells (Fig. 1a, b). The CTC selection devices were made from cyclic olefin 
copolymer (COC) via hot embossing, and each device’s surfaces were covalently decorated 
with a single mAb type (see Methods).17, 20 Blood entered the first CTC selection device 
through a single inlet channel, passed through a parallel array of 50 sinusoidal mAb-laden 
selection channels at 2 mm/s (1.5 ml/h) (Fig. 1c),15, 16 and exited through a single outlet 
channel, which then fed the second device that was identical except for the identity of the 
selection mAb. After blood processing and washing, the chips could be disconnected so each 
CTC subpopulation could be interrogated independently, data which would have been 
obscured by immobilizing both mAbs in one device.
Several aspects of the sinusoidal architecture were optimized (125 µm radius of curvature, 
25 µm width, and 150 µm depth) to maximize recovery, throughput, and purity (Fig. 1b, d).
15, 16, 23 The CTC affinity-selection process can be separated into two parts, initiation of 
contact between a CTC and the mAb-coated surface and successful binding of the rolling 
CTC with surface-confined mAbs. For the first process, the sinusoidal architecture generated 
centrifugal forces (Fc) to propel CTCs towards the mAb-coated channel walls with a 
magnitude that varies with cell diameter, density, and forward velocity (V). For a 16 µm 
CTC traveling at 2 mm/s, the resultant centrifugal velocity (Vc) is 1.9 µm/s, four times 
greater than an 8 µm leukocyte. Channel width is critical to Fc’s effectiveness. In 25-µm 
wide channels, only a 4.5 µm shift in position is needed for a 16 µm CTC to interact with the 
wall, and a 15 s residence time is provided to produce a Vc of 1.9 µm/s that helps facilitate 
CTC-mAb interactions.16
While Vc can be enhanced by increasing the cell’s forward velocity V, the trade-off is lower 
probability of successful binding of rolling CTCs and surface-bound mAbs. The binding 
dynamics of CTC microfluidic affinity-selection can be described by the Chang–Hammer 
model,24 (see Eq. 1) which balances mAb-antigen binding kinetics, the residence time of the 
traveling CTC near a mAb, and the number of antigens on a CTC, with recovery becoming 
less probable at very high linear velocities and low antigen expression.
PR = 1 − 1/e
NRLk f
V . (1)
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In Eq. 1, the probability (PR) of CTC recovery and the forward binding constant (kf) are a 
function of how often Ab-antigen interactions occur and how probable a given binding event 
is considering the balance of the Ab-antigen binding kinetics with the reaction time. 
Recovery should: (i) decrease as the cell’s velocity (V) is increased due to shorter reaction 
time, and (ii) increase with the surface density of antigens expressed on the CTC (NR). As 
the CTC rolls over the surface with increasing length (L), PR increases and leads to higher 
recovery.
An aspect of the sinusoidal CTC chip that evolved from the Chang–Hammer model is 
related to long rolling distances of CTCs over the continuous microfluidic surface, which 
improves recovery by accumulating more potential binding events (Fig. 1e).16 This 
accumulative effect of long rolling distances in the sinusoidal architecture (>250 µm) is 
especially important to provide high recovery of CTCs with low antigen expression (limit of 
700 molecules per 16 µm CTC under shear force)19 and enables operation at relatively high 
V (2 mm/s),15, 16 which maintains high throughput (1.5 ml/h) and generates high fluidic 
shear stress (13.3 dynes/cm2) that disrupts non-specific adsorption of leukocytes to the 
mAb-coated COC polymer surface and yields the sinusoidal technology’s uniquely high 
purity.25
CTC recovery and orthogonality of the dual selection strategy
Two breast cancer cell lines, Hs578T and SKBR3, representing FAPα + CTCs (CTCFAPα) 
and EpCAM + CTCs (CTCEpCAM), respectively, were chosen to evaluate cell recovery and 
cross-reactivity using the dual selection strategy. These cell lines were characterized by 
multi-parameter flow cytometry, immunophenotyping, and mRNA gene expression 
(Supplementary Fig. S2A–C).
For Hs578T and SKBR3 cells spiked into healthy donors’ blood, the average recovery (±SD) 
were 75 ± 8% and 77 ± 2%, respectively. For comparison, the recovery of MCF-7 cells 
(higher expression of EpCAM than SKBR3) using the same architecture device and 
modification chemistry was 83 ± 5%.17 The purity of the selected CTC fractions seeded at 
~100 cells/ml into healthy donors’ blood was 93 ± 3% (Hs578T) and 91 ± 4% (SKBR3). 
Additionally, the cross-reactivity of Hs578T cells on the anti-EpCAM selection chip was 4 
± 2% (n = 3), and SKBR3 cells on the anti-FAPα selection device was 8 ± 3% (n = 3).
We selected both FAPα+ and EpCAM+ cells from a single blood sample by arranging two 
microfluidic devices in series. The effect of the order in which the devices were positioned 
on CTC recovery was investigated; no preferential CTC isolation on the first chip was 
observed (Supplementary Table S1). Also, there was no statistical difference between the 
order of the chips. The dual selection strategy reproducibility for each chip produced an 
RSD of 25% (n = 33). For these studies, the FAPα selection chip was positioned first in the 
series.
CTC dual selection from clinical samples
In a pilot clinical study, we analyzed blood from 11 healthy donors and 6 patients with 
benign disease (Supplementary Tables S2, S3), 5 L-PDAC, 10 M-PDAC, 3 localized 
colorectal cancer (L-CRC), 3 metastatic CRC (M-CRC), 10 metastatic breast ductal 
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carcinoma (M-BC), 8 metastatic chemotherapy naïve EOC (M-EOC-no-chemo), 5 
metastatic EOC that received neo-adjuvant chemotherapy (M-EOC-chemo), 3 localized 
chemotherapy-naïve EOC (L-EOC-no-chemo), and 5 castration resistant prostate cancer 
(CRPC) patients (Supplementary Tables S4–S8). Each CTC subpopulation was enumerated 
independently. CTCs were stained for CKs, CD45, and 4′,6-diamidino-2-phenylindole 
(DAPI) or counted using an impedance sensor following enzymatic release from the capture 
surface.17 Impedance sensing is a detection strategy of single cells that obviates the need for 
staining, which may interfere with the molecular analyses.15, 17 For the present study, 
following CTC isolation, cells were released from the device using trypsin and infused 
between electrodes operated at 40 kHz; each cell generates a detectable voltage pulse that 
correlates with cell size. An example of an impedance trace for CTCs is presented in 
Supplementary Fig. S3. We compared both CTCFAPα and CTCEpCAM counts obtained via 
staining and impedance sensing by performing duplicate analyses for randomly selected 
samples (Supplementary Table S9). The CTC counts obtained by both methods were similar, 
and any differences most likely reflect Poisson statistics.
In blood from healthy donors, no CTCFAPα or CTCEpCAM were detected. The mean for 
CTCFAPα and CTCEpCAM in patients with non-cancer disease was 1.8/ml and 2.6/ml, 
respectively (Supplementary Table S10). CTC test positivity and test specificities were 
determined by establishing a threshold value based on 3 × SD for cells detected in healthy 
and non-cancer disease patients. The test specificity at this threshold was 100% (n = 17). 
Dual CTC selection provided 100% test positivity for patients with all malignancies but M-
BC (Fig. 1h), which yielded 80%.
For cancer patient samples, the number of CTCFAPα and CTCEpCAM varied with the disease 
type (Fig. 1f). Pairwise statistical analysis showed a significant difference between CTCs 
detected in cancer patients and healthy donors or patients with non-cancer disease 
(Supplementary Table S11).
CTCFAPα were most prevalent in M-CRC (26–49/ml), while CTCEpCAM were most 
abundant in chemotherapy-naïve M-EOC (65–680/ml; Supplementary Table S10). In M-
EOC, the median CTCEpCAM was higher for chemotherapy-naïve patients compared to 
patients undergoing chemotherapy (129/ml vs. 42/ml, p = 0.007). Conversely, there was no 
change observed in CTCFAPα counts between these two groups (36 vs. 32/ml). CTCFAPα 
numbers were 2 × lower in L-EOC-no-chemo patients (18/ml; Supplementary Fig. S4A, B).
The recoveries of CTCs evaluated from clinical samples, determined using the “self-
referencing” method (see SI),18 for randomly selected samples were found to be 79 ± 7% (n 
= 3) and 87 ± 2% (n = 3) for CTCFAPα and CTCEpCAM, respectively. The difference in the 
clinical recovery arises from dissimilarities in the level of antigen expression and cell size 
within a CTC subpopulation. The purity determined for each individual selection bed, 
defined as [CTCs/(CTCs + leukocytes)], are reported in Fig. 1h with WBCs counts reported 
in Supplementary Tables S14–S19.
Fluorescence images of CTCFAPα and CTCEpCAM isolated from MCRC, M-BC, and M-
EOC-no-chemo (Fig. 2) showed that both subpopulations displayed characteristics attributed 
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to a CTC (i.e., large nuclear/cytoplasm ratio). However, differences in morphological 
features between CTCFAPα and CTCEpCAM were not conclusive mainly due to the nature of 
the affinity-based selection process, which can change the appearance of cells upon antigen–
mAb binding to solid surfaces in the presence of shear forces. No CTCs were identified that 
were triple stained (DAPI+, CK +, CD45+) or showed only nuclear staining.
Immunophenotyping of CTC subpopulations in clinical samples
Selected CTCs were immunophenotyped for expression of CD45, pan-CK (epithelial 
marker), and VIM (mesenchymal marker). The fluorescence intensity was normalized (see 
Methods) and CTCs were classified as showing no (−), medium (+) or high (++) expression 
of the appropriate marker. Examples of different phenotypes are shown in Fig. 3. Figure 3a 
shows two FAPα+ cells isolated from a pancreatitis patient. These rare cells were CK−/VIM
++/CD45− with a low nuclear-to-cytoplasmic ratio and were classified as circulating 
fibroblasts and not CTCFAPα.
In L/M-PDAC patients, most CTCFAPα were VIM++ and CK+ (Fig. 3b). CTCEpCAM with 
this phenotype were found in M-PDAC, but not in L-PDAC patients. In L-PDAC, the 
CTCEpCAM dominating fraction equally expressed VIM and CK with some cells VIM- and 
CK++.
For a triple negative M-BC patient, the majority of CTCFAPα showed VIM++ and CK+ with 
the remaining CTCs equally expressed CK and VIM (Fig. 3b). CTCEpCAM showed all 
phenotype combinations.
These results indicated the presence of different phenotypes among CTCFAPα and 
CTCEpCAM; VIM++ and CK+ implied a mesenchymal type, VIM− and CK++ an epithelial 
one, and a third phenotype showing co-expression of CK and VIM suggested a cell 
undergoing epithelial–mesenchymal transition (EMT).2
Longitudinal tracking of PDAC patients
Figure 4a–c shows longitudinal tracking results for five PDACpatients. The first CTC test 
for 3/5 of these patients was obtained preoperatively on the day of surgery. It appeared that 
CTCFAPα were the dominating population at that time as indicated by CTCFAPα/CTCEpCAM 
ratio (defined as ϕ) ranging between 1.2 and 2.3 (Fig. 4b, c).
Figure 4a shows longitudinal tracking of M-PDAC patient #25. Levels of CTCFAPα 
decreased 60 days after the initial analysis with no significant change observed on day 129. 
CTCEpCAM increased slightly; computed tomography (CT) imaging was consistent with 
stable disease over this time period and ϕ was 0.3. However, CTC analysis on day 171 
showed a nearly 2-fold increase in CTCFAPα and a significant drop in the CTCEpCAM 
burden, with ϕ equal to 2.3. This patient’s disease later showed progression by CT imaging. 
CA19-9 levels were low and continually decreased over the entire testing period (normal < 
35 U/ml).
Figure 4b shows results for L-PDAC patient #45. Pre-operative CTCFAPα was 20/ml; 
CTCEpCAM was 12/ml (ϕ = 1.7); and CA19-9 was 1764 U/ml. On day 162, the CTC burden 
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was ~10/ml for both subpopulations (ϕ = 0.6), and CT imaging was not definitive for disease 
recurrence. On day 208, CTCFAPα counts increased to 20/ml, while CTCEpCAM were 7/ml 
(ϕ = 2.7). CT imaging for this patient thereafter showed metastatic disease. CA 19-9 levels 
decreased 2-fold from the pre-operative level but remained high at 831 U/ml. In PDAC 
pt#45 and #25 CA 19-9 levels did not correlate with disease progression as determined by 
CT.
In L-PDAC patient #48 on day 85, both CT scan and CTC analysis were performed. Both 
CTC subpopulations were enumerated (ϕ = 1.2), and the results of CT imaging indicated 
metastatic disease. A subsequent CTC test administered on day 230 showed similar 
CTCFAPα burden (26/ml) and a decrease in CTCEpCAM numbers (ϕ = 2.2, Fig. 4c), and CT 
imaging determined disease progression.
In L-PDAC patient #66, the ϕ was 1.2 on the day of surgery. It decreased to 0.6 on day 96 
following surgery, but increased again to 1.5 on day 194. CTC testing on day 194 detected 
the same burden of CTCEpCAM (~51/ml) as found on day 96, but a 2.5-fold increase in 
CTCFAPα burden (31 v 79 CTCFAPα/ml) was observed (Fig. 4c). At that time (day 194), 
disease progression was determined via CT imaging.
In the fifth patient tested in the longitudinal study (patient #46), the ϕ was 2.3 on the day of 
surgery, indicating a dominant CTCFAPα subpopulation. Nineteen and 53 days following 
surgery, post-operative chemotherapy and radiation, the CTC burden was low as only 3–5 
CTC/ml were detected for both subpopulations. When the CTC test was performed at day 
207, the counts for both CTC subpopulations increased (14/ml for CTCFAPα and 26/ml 
CTCEpCAM), with CTCEpCAM being the dominating population (ϕ = 0.6, Fig. 4c). About a 
year following surgery, this patient’s disease was classified as stable by CT.
For all aforementioned PDAC patients, we analyzed CTC results for which clinical notations 
were available: (i) samples acquired pre-operatively (localized disease), CT imaging 
indicating (ii) stable disease or (iii) metastasis (Supplementary Fig. S4). For this data set, the 
tandem analysis of both CTCFAPα and CTCEpCAM subpopulations appeared to be a better 
indicator of PDAC disease state than the analysis of either subpopulation alone (Fig. 4c and 
Supplementary Fig. S5).
CTC next generation sequencing (NGS) and mutation detection using the polymerase 
chain reaction/ligase detection reaction (PCR/LDR)
When isolated CTC fractions are of low purity, single-cell picking must be performed to 
eliminate wild type background. Given the high purity afforded by the sinusoidal 
microfluidic, we sought to obviate single cell picking and release CTCs in bulk from the 
microfluidic chip, and performing whole genome amplification (WGA) and NGS on the 
bulk affinity selected CTC subpopulations. We surveyed both CTC subpopulations isolated 
from a chemotherapy-naïve L-EOC patient (CTCFAPα = 105, CTCEpCAM = 717). Deep read 
depths (9900–65,000) allowed for high fidelity mutation detection. The CTCFAPα and 
CTCEpCAM gDNA contained the same missense somatic mutations in TP53 and CDH1 
genes and other SNPs, suggesting these CTCs had the same origin (Supplementary Table 
S12).
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We also targeted KRAS mutations in CTCs using PCR/LDR (see Methods), a sensitive 
method due to dual amplification, to identify mutations in low copy numbers of DNA (Fig. 
5a).26 By designing different length discriminating and common-fluorescently labeled 
primers, the LDR products differed in size depending on the specific KRAS mutation 
(Supplementary Table S13). LDR products were detected by capillary gel electrophoresis 
(Fig. 5b). gDNA from cell lines of known KRAS genotype (HT29—wild-type (wt) and 
LS180—mutated (mt) G35A) provided controls. HT29 gDNA showed peaks corresponding 
to 50 and 67 nt fragments indicating wt exon 1 codon 12 (wt35 and wt34, Supplementary 
Table S13), while LS180 gDNA showed an additional product of 44 nt (Fig. 5b) indicating 
mt G35A in this codon in agreement with the literature.27 LDR reactions without gDNA 
showed no products (Fig. 5b).
CTC subpopulations from one M-CRC, L-CRC, L-PDAC and two M-PDAC samples were 
independently genotyped (Fig. 5c). Tumor tissue was not available for testing.
The prevalence of KRAS mutations in PDAC is nearly ubiquitous and represents the earliest 
genetic alteration in this disease.28 In M-PDAC patient #68, both subpopulations showed 
three mutations in KRAS (Fig. 5b). However, in patients #66 and #67, CTCEpCAM were not 
mutated, whereas CTCFAPα showed G35A and G35T KRAS mutations. Multiple mutations 
are indicative of cancer cell aneuploidy, and this “polyclonality” of KRAS SNPs is a 
common feature in PDAC patients.29
For CRC patients, KRAS mutations are often found in codon 12 (80%), most frequently 
G35A and G35T.30 CTCFAPα from M-CRC patient #118 was wt KRAS; however, 
CTCEpCAM showed a G35A mutation. In L-CRC patient #135, we detected mt G34C in 
CTCFAPα and mt G35A in CTCEpCAM (Fig. 5c).
Gene expression analysis of FAPα and EpCAM CTCs
While the molecular profiling of CTC was performed to obtain information on orthogonality 
or dissimilarity of evaluated CTC subpopulations, these data will demonstrate the 
translational capacity and clinical utility of molecular profiling CTCs isolated using the 
sinusoidal microfluidic device.
We evaluated possible mRNA expression changes due to microfluidic isolation using cell 
lines. Relative expression of mRNA for selected genes assessed for Hs578T and SKBR3 
cells harvested from culture and affinity isolated on a microfluidic chip indicated no 
significant differences for the tested genes (Supplementary Fig. S6), indicating no obvious 
influence of the affinity selection process on mRNA expression.
CTC subpopulations were tested for their mRNA expression in five M-PDAC and two M-
CRC patients (Fig. 5d, e and Supplementary Fig. S7). Gene expression patterns differed 
between CTCFAPα and CTCEpCAM subpopulations and were distinct from the patient’s T 
cells and buffy coat. EpCAM mRNA expression for the CTCEpCAM subpopulation was 10-
fold higher than CTCFAPα for both cancer types, and FAPα mRNA was not found in the 
CTCEpCAM subpopulation. Both results agreed with immunophenotyping; when CTCs were 
stained with fluorescently-labeled anti-EpCAM mAb, 89 ± 11% of CTCEpCAM and 12 ± 6% 
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CTCFAPα had detectable EpCAM. FAPα mRNA expression was exclusively observed in 
CTCFAPα but was rather low because the FAPα protein is a product of alternative splicing of 
ten different mRNAs. (http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?
db=human&c=Gene&l=FAP) When two variants were tested in the Hs578T cell line, both 
FAPα mRNA were observed (Supplementary Fig. S2C). VIM mRNA was expressed higher 
in CTCFAPα than CTCEpCAM in M-PDAC; however, VIM expression was high in both 
subpopulations in M-CRC. mRNA expression profiling included stem cell markers (CD133, 
CD24, and CD44). In M-PDAC, CD133, CD24 mRNA was highly expressed in both 
subpopulations, with CD44 showing expression only in CTCEpCAM. Both subpopulations of 
CTCs in M-CRC showed expression of CD24 but lacked CD44 and CD133 (Supplementary 
Fig. S7A).
Both CTC subpopulations from M-PDAC and M-CRC patients lacked CD34 mRNA, 
suggesting absence of endothelial cell character and no significant contamination from 
hematopoietic cells. CD34 mRNA was expressed, as expected, in the M-PDAC buffy coat 
(Supplementary Fig. S7A).
KRAS mRNA in the CTCEpCAM subpopulation was highly expressed when compared to 
CTCFAPα for M-CRC (Supplementary Fig. S7A), which contrasted to M-PDAC. However, 
when we evaluated expression in individual patients (Fig. 5d), we observed that the wt 
KRAS gene in CTCEpCAM was overexpressed, while for the mutated KRAS in CTCFAPα, 
expression was 10-fold lower. Similar observations were made for the L-PDAC patient. 
Overexpression of wt KRAS suggests activation of downstream signaling pathways.31
We tested PSA and PSMA mRNA gene expression in a CRPC patient (Supplementary Fig. 
S7B). PSA and PSMA mRNA were expressed in both CTCFAPα and CTCEpCAM, suggesting 
these cells originated from the prostate tumor environment as PSMA and PSA mRNA 
expression is observed in normal prostate, hyperplastic, and invasive prostate carcinomas.32 
CTCFAPα were also stained with a fluorescently-labeled PSMA mAb, which confirmed the 
presence of this protein.
CTC isolation from PDX: Do CTCFAPα originate from human tumor or mouse-activated 
stroma?
FAPα is considered a marker of cancer-associated fibroblasts (CAFs), but it is also 
expressed by pericytes, fibrocytes, or fibroblasts during wound healing.33 CAFs or 
circulating fibroblasts are typically identified as expressing FAPα/SMAα/VIM but lacking 
CK and CD45,34 and are genetically stable.33 Fibrocytes detected in tumor stroma or bone 
marrow are FAPα+/CD34+/CD45+ while the FAPα+/CD34+/CD45− phenotype suggests a 
mesenchymal stem cell.35, 36 Isolated CTCFAPα expressed VIM, CK, but no CD45 
(phenotyping and gene expression) and were CD34− as determined by mRNA expression 
(i.e., were different from fibrocytes or CAFs). Additionally, mutations detected in CTCFAPα 
in M-CRC and L/M-PDAC and L-EOC implied neoplastic character, unlike CAFs.
We used PDX mouse models to more directly test whether isolated CTCFAPα originated 
from human tumor or activated stroma (i.e., mouse stroma). We note that the anti-human 
mAbs used for isolation in this study will cross react with murine FAPα and EpCAM 
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antigens; (human FAPα shares 90% AA identity with mouse FAPα, and human/mouse 
EpCAM share 82% aa sequence identity). CTC originating from mouse tissue and human 
tumor will be detected. We isolated CTCs from PDX models of basal-like breast cancer (Fig. 
6a–c) and extracted gDNA from CTC subpopulations and tumor tissue. CTCs gDNA was 
subjected to WGA, PCR amplification with human-specific primers, and sequencing. The 
sequences were evaluated for homology to human and mouse gDNA of the same exon. The 
DNA from both CTCEpCAM and CTCFAPα subpopulations and tumor showed human 
sequence (Fig. 6d), suggesting CTCFAPα did not originate from mouse stroma surrounding 
the tumor.
It is possible that CTCFAPα originate from epithelial precursor cells or are a product of 
independent event in the epithelium, or could be precursor cells themselves with the ability 
to differentiate and clonally expand; these cells could represent a subpopulation of cancer 
cells undergoing EMT or mesenchymal–epithelial transition.37
DISCUSSION
The challenge associated with CTCs as biomarkers has been modest clinical sensitivity with 
the FDA-approved platform. The question arises: does the biology limit the CTC burden or 
is the analytical platform used for their isolation limiting? Indeed, many microfluidic 
technologies have shown higher clinical sensitivity/CTC test positivity compared to the 
FDA-approved test.6, 38 A challenge with CTC assays is that in many cases, only a single 
selection marker is used for isolation despite the phenotypically diverse microenvironment 
of the tumor. We addressed this issue by using a CTC dual selection strategy that employed 
discrete microfluidics designed to independently select two phenotypically distinct 
subpopulations; CTCEpCAM and CTCFAPα, which represent epithelial and mesenchymal-like 
cancer cell phenotypes, respectively. Dual selection with the use of discrete microfluidics 
provided high CTC test positivity and specificity (Fig. 1h). The orthogonality of these two 
subpopulations was demonstrated through differential expression of EpCAM and FAPα 
mRNA and immunophenotyping with anti-EpCAM and anti-FAPα antibodies (Fig. 2, 
Supplementary Fig. S7A). For CRPC patients, PSA and PSMA mRNA expression in 
CTCFAPα indicated that these cells originated from the prostate tumor (Supplementary Fig. 
S7B), which is not unprecedented as EpCAM-/PSMA+ prostate cancer CTCs have also been 
identified by others.39
FAPα as a new marker for CTC affinity selection was specific as only a few hematopoietic 
cells were co-isolated from blood of healthy donors and non-cancer patients. Although 
circulating fibroblasts (FAPα+/α-SMA+/CK−/CD45−) were found in metastatic cancer 
patients (median = 4/7.5 ml) using filtration,34 these cells were not consistently isolated in 
our studies. These cells were CK −/CD45−/VIM+, and with this distinct phenotype, we 
could distinguish these cells from CTCs without compromising the integrity of the dual 
selection assay.
High purities of both CTC subpopulations allowed for bulk molecular analyses, obviating 
the need for single cell analysis. For example, a chemotherapy naïve L-EOC patient sample 
with high CTCFAPα and CTCEpCAM counts underwent WGA of gDNA and targeted-exome 
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NGS; similar mutational profiles between the CTC subpopulations suggested a common 
origin. It is possible that unique mutation profiles in subclones of CTCFAPα and/or 
CTCEpCAM subpopulations were too infrequent to be detected by bulk analysis. Even with 
the purity achieved herein, detecting mutations by NGS in low frequency clones would incur 
requiring a more rigorous workflow including single CTC picking, WGA, NGS, and 
comparative analysis of single CTC mutations (consensus sequencing). Unfortunately, 
associated with this workflow would be amplification errors and low success rates associated 
with WGA.40 The costs and intense labor associated with these strategies would hinder 
clinical translation. Alternatively, PCR/LDR provides enhanced sensitivity for low frequency 
mutations, thereby providing translatable analysis of actionable and highly conserved 
mutations, such as KRAS.
KRAS mutational status in CTCs has been shown to have a high concordance with the 
primary tumor (~90%).30 Thus, in the absence of a primary tumor or anatomically 
inaccessible organs, decisions regarding treatment appropriateness could be made using 
CTCs.30 This is important as patients who harbor KRAS mutated genes derive minimal 
benefit from anti-EGFR mAb therapy. We detected KRAS mutations in CTCFAPα and 
CTCEpCAM but not always in both CTC subpopulations. For example, in two PDAC patients 
who underwent multiple rounds of chemotherapy, KRAS mutations were found in CTCFAPα 
but not in CTCEpCAM (Fig. 5). Thus, the testing of both subpopulations would be advisable 
to secure better concordance with the primary/metastatic sites and provide information for 
combination therapies. These differences in mutational status are not clear but may be a 
result of chemotherapy or reflect different cancer cells’ pre-chemotherapy KRAS 
dependence.41 Interestingly, M-EOC patients were found to have a 3-fold lower median 
CTCEpCAM count following chemotherapy treatment compared to chemotherapy naïve 
patients, while CTCFAPα median counts for these cohorts remained unchanged, potentially 
suggesting CTCEpCAM were more sensitive to chemotherapy. Further studies should address 
whether CTCFAPα are equipped with properties that enable chemoresistance.
Recently, the presence of both epithelial and quasi-mesenchymal subtypes of cancer cells 
was identified in PDAC42; selection strategies targeting EpCAM only may not fully 
recapitulate the primary/metastatic tumor and provide insufficient information for patients 
with a non-epithelial PDAC subtype. We longitudinally tracked CTCFAPα and CTCEpCAM in 
L/M-PDAC patients and observed that CTCEpCAM burden alone was not indicative of 
disease status (Fig. 4); however, the ratio of CTCFAPα to CTCEpCAM better correlated with 
disease progression (Supplementary Fig. S5).
A dual selection strategy with orthogonal markers offered high test positivity for CTCs for a 
several cancers, even early stage disease. In addition, we demonstrated the ability to 
efficiently isolate CTCs from small blood volumes in PDX mouse models. The sinusoidal 
microfluidic chips provided high recovery and purity of CTCs for both localized and 
metastatic cancers to allow for “bulk” molecular profiling. Further, the use of discrete 
microfluidics for dual selection of CTCs of different phenotypes obviated the loss of 
subpopulation-specific distinctions in therapy response due to ensemble averaging, which 
would occur if mixed-monolayers of mAbs were poised within one microfluidic device.
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Surveillance of both CTC subpopulations (epithelial and mesenchymal) can deliver more 
phenotype-specific insights into cancer progression and chemotherapy resistance, which 
cannot be discerned using other types of circulating markers, e.g., cell free DNA, because 
their origin cannot be associated with a certain tumor cell type.
METHODS
Clinical samples
Healthy donors’ blood samples were obtained from the UNC Cancer Hospital Blood Bank. 
Blood from patients diagnosed with non-cancer or cancer were collected according to an 
approved UNC Institutional Review Board procedure. Written informed consent was 
obtained from all patients included in the study before enrollment. Peripheral blood samples 
were drawn by venipuncture into Vacuette® containing EDTA (Greiner) tubes. Tables S2–S8 
provide annotation data on the patients enrolled in this study. Supplementary Tables S14–
S19 provide raw CTC enumeration data.
Reagents and chemicals
COC (6013S-04) was purchased from TOPAS Advanced Polymers (Florence, KY). 
Chemicals and reagents used in these studies included Micro-90, reagent-grade isopropyl 
alcohol (IPA), phosphate-buffered saline pH = 7.4 (PBS), 2-(4-morpholino)-ethane sulfonic 
acid (MES), 7.5% bovine serum albumin (BSA), Triton X-100, paraformaldehyde solution 
(Sigma-Aldrich, St. Louis, MO), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 
N-hydroxysuccinimide (NHS) (Pierce, Rockford, IL), mouse anti-human EpCAM mAb 
(R&D Systems, clone#158210, Minneapolis, MN), mouse anti-human Fibroblast Activation 
Protein α (FAPα) mAb (R&D Systems, clone#427819), mouse monoclonal anti-Fc blocker 
IgG (R&D Systems,), DAPI, anti-CD45-FITC mAb (eBioscience, clone HI30), anti-CK 8 
and 19 mAb (CK8/19-eFluor®615, clone#LP3K, BA17), anti-pan-CK-(AE1/AE3) 
eFluor®615 mAb (eBioscience, San Diego, CA), anti-human EpCAM-eFluor®660 mAb 
(eBioscience, clone#1B7), anti-human vimentin-Alexa Fluor®488 mAb (clone 280618 
(R&D), and anti-human vimentin-APC mAb (R&D Systems, clone#280618). Nuclease-free 
water and microtubes (Ambion, Foster City, CA) were used for preparation and storage of 
all samples and reagents.
Fabrication and assembly of the CTC microfluidic devices
Microfluidic devices used COC substrates that were hot embossed from a metal mold 
master. The chip design was a Z-configuration consisting of a 26.3mm× 20.5mm footprint 
with inlet and outlet channels (20.5mm long, 400 µm wide, and 150 µm deep) connecting a 
series of 50-sinusoidal channels that in concert formed the CTC selection bed. Each 
sinusoidal channel was 30.6mm long, 150 µm deep and 25 µm wide.
The surface area of the CTC selection bed was 596 mm2 (11 mm2/channel). The chip’s total 
volume was 9.4 µl (138 nl/channel) with a 2.5 µl volume for the inlet/outlet channels. 
Microfluidic devices and the planar substrates from which they were made were sonicated in 
10% Micro-90 for 10 min, rinsed with IPA and DI water and dried at 70 °C. Devices and 
cover plates, both consisting of COC, were thermally fusion bonded between two glass 
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plates in a convection oven at 131 °C for 30 min after which, they were UV/O3 activated for 
15 min (22 mW/cm2 at 254 nm) in a home-built activation chamber equipped with a quartz, 
low-pressure Hg lamp. This activation protocol generated a functional scaffold of surface-
confined carboxylic acids to which selection mAbs could be attached. Devices were 
modified using EDC–NHS chemistry (20 mg/ml EDC, 2 mg/ml NHS, in 100 mM MES, pH 
4.8) followed by incubation with a solution of mAb (0.5 mg/ml; 150mM PBS buffer, pH 7.4) 
overnight at 4 °C.
Fluid dynamic simulations through sinusoidal channel architectures
The Chang–Hammer model24 (see Eq. 1) was used to investigate the dynamics of CTC 
affinity-selection as described elsewhere.16 Parameters for the simulation not provided by 
Chang–Hammer24 were: a 16-µm diameter CTC, mean EpCAM expression of 49,700 
EpCAM molecules/cell,43 a kin of 2.5 × 104 M−1 s−1 for antibody-EpCAM binding kinetics,
44 and variable rolling distance.
Isolation of CTCFAPα and CTCEpCAM via dual selection
Whole blood was processed using the dual selection strategy within 3 h following collection. 
Usually 2ml of blood was infused into the microfluidic device yielding a linear velocity of 2 
mm/s (25 µl/min). A post-isolation rinse was performed at 4 mm/s with 2ml PBS/0.5% BSA. 
Affinity-bound cells were identified and enumerated via staining or impedance sensing.
CTC staining and imaging
Cells were stained with anti-CD45-FITC mAbs (clone HI30; BioLegend, San Diego, CA), 
fixed with formaldehyde (2%), permeabilized with 0.1% Triton X-100, and stained with a 
mixture of CK 8, (clone C-46), 18 (clone DA/7), 19 (clone A53-B/A2), or pan-CK-
eFluor®615 (clone C-11; BioLegend), anti-Vimentin-Cy5, and DAPI. In some cases, cells 
were stained with anti-EpCAM-Cy5 or FAPα via a secondary IgG mAb. CTC visualization/
enumeration was performed using an inverted Olympus IX71 microscope (Center Valley, 
PA) equipped with a high resolution (1344 × 1024) CCD camera (Hamamatsu ORCA-03G) 
and a mercury arc lamp. Images were collected, background corrected, normalized, and 
analyzed using Metamorph software (Molecular Devices Inc.). In ImageJ images were 
converted to 8-bit type, a gray scale values of the signal were read from the line plots and the 
phenotypes were classified as no signal (−) (0–30 level), weak (+) (31–100 level), and strong 
(++) (101–256 level).
Impedance detection of CTCs
Following CTC selection and bed washing, CTCs could be released from the capture surface 
of the sinusoidal channels with buffer consisting of 0.25% w/v trypsin in 25mM TRIS/
192mM glycine buffer (pH 7.4). Released CTCs traversed through an impedance sensor and 
an electrical signal was recorded using in-house designed electronics. Impedance responses 
from CTCs were scored when the signal-to-noise ratio exceeded 3:1 using Matlab.
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RNA isolation and reverse transcription (RT)—quantitative PCR (RT-qPCR)
Cells were lysed and RNA was extracted from the lysate followed by RT performed using 
the Cell-to-Ct Kit (Life Technologies). A volume of2 µl of synthesized first strand cDNA 
was used for qPCR performed with a Universal SYBR green mix (BioRad) using a total 
reaction volume of 10 µl. RT-qPCR was performed using an Agilent HT7900 instrument 
(Applied Biosystems, Foster City, CA, USA). Primers were obtained from RealTime-
Primers.com.
The qPCR steps consisted of 20 s at 95 °C and 40 cycles each for 3 s at 95 °C and 15 s at 
58 °C and 15 s at 68 °C. Expression data were calculated using the comparative threshold 
cycle (Ct) method. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the 
endogenous control. The Ct data for GAPDH was used to create ΔCt values [ΔCt = Ct (target 
gene) −Ct (GAPDH)]. Relative quantification values were calculated using the equation: 
2−ΔCt.
Genomic DNA isolation, whole genome amplification, and NGS
gDNA was extracted and purified using the Quick-gDNA™ MicroPrep kit (Zymo 
Research). WGA was performed using the Illustra Single Cell GenomiPhi DNA 
Amplification Kit (GE Healthcare) following manufacturer protocol. Samples were 
subjected to targeted-exome NGS on a Miseq® using the TruSight™ Tumor 26 Sequencing 
Panel (Illumina).
PCR/LDR assay
Cell lines of known KRAS genotype (HT29, wild-type and LS180—G12V) were secured 
from the Tissue Culture Facility at UNC. gDNA from the cell lines and CTCs was extracted 
using an Agencourt DNA isolation kit (Beckman–Coulter). PCR was performed with DNA 
in a total volume of 20 µl using Taq 2 × Master Mix (New England Biolabs, Ipswich, MA). 
PCR cocktails consisted of 2 µl of primers, 10 µl Taq 2× Master Mix, 6 µl nuclease free 
water and 2 µl gDNA. PCR was carried out in a thermal cycler (MJ Research Inc.) with the 
following steps: denaturation at 94 °C for 2.5 min followed by 40 cycles of denaturation at 
94 °C for 15 s; annealing for 30 s at 58 °C and extension at 72 °C for 30 s. A final extension 
at 72 °C for 7 min was followed by a cooling step at 4 °C. KRAS primers were obtained 
from IDTDNA: forward primer 5′ AAC CTT ATG TGT GAC ATG TTC TAA TAT AGT 
CAC 3′ and reverse primer 5′ AAA ATG GTC AGA GAA ACC TTT ATC TGT ATC-3′. 
PCR products (290 bp) were electrophoresed at 8.3 V/cm in 1 × TBE using a 4% agarose gel 
with ethidium bromide (Lonza) staining. Amplicons were indexed against a DNA sizing 
ladder 50–766 bp (New England Biolabs). Images were collected using a Logic Gel imaging 
system (Eastman Kodak).
LDRs were carried out in a 20-µl volume with North9° Ligase. The LDR cocktail contained 
discriminating and common primers 4 nM each, amplicons 0.6–1 ng (3–5 fmol), 40 units of 
DNA ligase and buffer. Thermocycling conditions were 94 °C for 1 min and 59 °C for 4 min 
that was repeated 20-times. Common primers for codon 34 and 35 were Cy5-labeled. 
Discriminating primers were design to produce ligated products with different sizes 
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(Supplementary Table S13). LDR products were separated using a Beckman CQ CE system 
and sized against the appropriate ladder.
Statistical analysis
Statistical analysis was conducted using a non-parametric U-test (Wilcoxon–Mann–Whitney 
test). For all analyses, p < 0.05 was considered statistically significant.
Data and materials availability
The authors declare that all data supporting the findings of this study are available within the 
paper and its supplementary information files. Discussion of data contained within this study 
or its relevant findings can be addressed by the corresponding author upon reasonable 
request.
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Refer to Web version on PubMed Central for supplementary material.
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Sinusoidal microfluidic device used in the study and summary of clinical results. a 
Schematic of the dual selection strategy using mAbs directed against FAPα and EpCAM 
cell-surface antigens. b SEM of the CTC selection microfluidic device. c Optical 
micrographs of the CTC selection microchip filled with whole blood, and the chip after 
rinsing with buffer. d An image (5×) of DAPI-stained Hs578T cells isolated within the 
channels of the microfluidic device. e Simulation of CTC recovery from blood at different 
translational velocities as a function of cell rolling distance along the mAb decorated 
surface. f Box plots for CTCs isolated from the blood of healthy donors, patients with non-
cancerous disease, CRPC, M- PDAC, M-CRC, M-BC, and M-EOC. CTC counts were 
normalized to 1ml of blood. g Test positivity in cancer patients’ blood using the single 
EpCAM approach and the dual selection strategy (test positivity based on the CTCFAPα 
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and/or CTCEpCAM counts exceeding a level that was 3× SD for counts from non-cancer 
patients)
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Phenotyping analysis in fluorescence microscopy. Images (40×) of CTCFAPα and 
CTCEpCAM isolated using the sinusoidal microfluidic chips and stained with a panel of 
markers: DAPI, anti-pan-CK-TR, anti-CD45-FITC, anti-VIM-FITC, anti-EpCAM-Cy5, and 
anti-FAPα-Cy5
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CTC phenotyping. a Fluorescence micrographs of cells isolated from a patient diagnosed 
with pancreatitis, and CTCFAPα and CTCEpCAM isolated from L/M-PDAC patients. All cells 
stained negative for CD45. b Immunophenotyping results of CTCFAPα and CTCEpCAM. The 
pie charts show the percent of CTCs with pan-CK and/or VIM expression for L-PDAC 
patient #66, M-PDAC patient #25, and M-BC patient #5
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Longitudinal tracking of CTCFAPα and CTCEpCAM numbers in the blood of PDAC patients. 
a M-PDAC patient #25. The first CTC analysis was performed during second-line therapy (t 
= 0). b L-PDAC patient #45. The first CTC analysis in this case was performed pre-
operatively on the day of surgery (t = 0). CA19-9 measurements (green stars) are shown 
when available. CTCFAPα = red dots, and CTCEpCAM = blue squares. Points are connected 
for ease of visualization, but do not represent any type of functional relationship between the 
individual data points. c A summary of all patients tested in this longitudinal study
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KRAS mutation detection. a Schematic of the polymerase chain reaction/ligase detection 
reaction (PCR/LDR) assay. b Electropherograms of LDR products for: No gDNA; HT29 
wt35 (50 nt); LS180 G35A (44 nt); M-PDAC CTCFAPα G35A (44 nt), CTCEpCAM G34C 
(61 nt); and CTCFAPα G35T (55 nt). The gray trace shows the DNA markers. The 
fluorescence intensity values are arbitrary. c Table summarizing PCR/LDR results for HT29 
and LS180 cell lines, M-CRC, L-CRC, M-PDAC, and L-PDAC CTCs. d RT-qPCR gene 
expression profiles for L-PDAC patient #66 and M-PDAC patient #67
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Phenotype, genotype, and CTCs from basal-like breast cancer PDX models. a IHC (400×) of 
tumor tissue in paraffin sections stained for FAPα, EpCAM, VIM, and pan-CK (scale bar = 
20 µm). b Fluorescence microscope images of CTCFAPα and CTCEpCAM isolated from the 
blood via cardiac puncture (scale bar = 15 µm). c CTCs isolated from two PDX models and 
a healthy NSG control. d Sanger sequencing traces for amplicons generated from exon 6 
TP53 DNA isolated from tumor tissue, CTCFAPα, and CTCEpCAM with primers designed for 
human sequence
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